EMA Recommends Eleven New Medicines

News
Article

The agency’s human medicines committee recommended drugs to treat breast cancer, lupus nephritis, type 2 diabetes and more.

The European Medicines Agency (EMA) announced on July 22, 2022 that its Committee for Medicinal Products for Human Use (CHMP) recommended approval for 11 medicines at its July 2022 meeting. The medicines treat a variety of conditions including cancer and type 2 diabetes.

The approved medicines included the following:

  • Celdoxome pegylated liposomal (doxorubicin hydrochloride) was approved for the treatment of metastatic breast cancer, advanced ovarian cancer, progressive multiple myeloma, and Kaposi's sarcoma.
  • Lupkynis (voclosporin) was approved to treat lupus nephritis, which is a condition caused by lupus where the kidneys are inflamed.
  • Mounjaro (tirzepatide) was approved for the treatment of adults with type 2 diabetes mellitus.
  • Opdualag (relatlimab/nivolumab) was approved to treat melanoma that has spread to other parts of the body and cannot be removed by surgery.
  • Tezspire (Tezepelumab) was approved as an add-on treatment in adult and adolescent patients with severe asthma.
  • Vabysmo (faricimab) was approved for the treatment of neovascular age-related macular degeneration and visual impairment due to diabetic macular edema in adults.
  • Thalidomide Lipomed (thalidomide) received a positive opinion for the treatment of multiple myeloma.

The CHMP also granted conditional marketing authorization for Tecvayli (teclistamab) for the treatment of adults with relapsed and refractory multiple myeloma, who have received at least three prior therapies. Tecvayli was processed through EMA’s PRIority MEdicines scheme, which provides early scientific and regulatory support for drugs that treat unmet needs.

Source: EMA

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes